DALLAS, Jan. 11, 2010 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring Immunomedics Inc. (Nasdaq:IMMU). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The full report is available at: http://www.beaconequity.com/i/IMMU
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
Immunomedics Inc. (IMMU) is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. The Company has developed a number of advanced technologies that allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create targeted agents.
Message Board Search for IMMU: http://www.boardcentral.com/boards/IMMU
In the report, the analyst notes:
"Pretargeting, as currently being developed by IMMU and IBC Pharmaceuticals LLC (a subsidiary of IMMU) scientists, may allow a new generation MAb-based diagnostic and therapeutic agents to be developed. This approach uses a 'two-step' protocol. A humanized bispecific antibody (bsAb), with at least one arm that recognizes a tumor-associated antigen and at least one other arm that recognizes an epitope on a diagnostic or therapy agent, is given as a first injection.
"An important project has been the development of improved agents for radioimmunotherapy (RAIT) by combining humanized MAbs with an optimal high-energy nuclide for RAIT application, yttrium-90. The group was responsible for the development of the Company's technology for the facile and quantitative yttrium-90 (Y-90) radiolabeling of the hMN-14 and hLL2 antibodies."
To read the entire report visit: http://www.beaconequity.com/i/IMMU
See what investors are saying about IMMU at penny stock forum.
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. Beacon Equity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.